Sunday

Some Gresham MAX stops to close starting Sunday

The Blue Line Improvement Project is nearing completion, but the final steps require a week-long closure of five Gresham stations.

GRESHAM, Ore. — Heads up for riders of the MAX Blue Line: TriMet is finishing some upgrades to the east end of the line in Gresham, starting this weekend. Part of the work involves rebuilding the only wooden trestle bridge in the entire MAX System.

The nearly year-long Gresham Max Improvement Project is in the home stretch, but that means there’s a week of station closures and shuttle-bus detours for riders who typically use stops from Ruby Junction to Cleveland Avenue — that’s the east end of the Blue Line.

Starting Sunday, TriMet will close those five stations to finish signal upgrades, improve the rail crossing at Eastman Parkway, which will close a section of the parkway for one day, and make repairs to a nearly 80-year-old trestle bridge over Fairview Creek, the only one of it’s kind in the entire MAX system.

Tyler Graf of TriMet says, “We acquired it in the early 80s as we were developing the MAX Blue line, and this will be the first significant refurb of that trestle in almost 40 years.”


In recent months, TriMet says about 2,100 riders a day commute on this part of the Blue Line. Shuttle buses will follow the normal MAX schedule closely, but it’s still good to plan ahead.

“We still encourage people to plan up to 15 extra minutes for their commutes, and understand that due to COVID-19 precautions, we are limiting the number of passengers on buses to between 19 and 24 passengers,” said Graf.

Regular service resumes Sunday, October 18, once the project is wrapped up.

RELATED: Metro sends historic bond to the November ballot

RELATED: MAX Blue Line project will impact

Continue Reading

ImmunoPrecise Antibodies CEO Dr. Jennifer Bath Appeared Live, Sunday October 4th, on Fox & Friends

VICTORIA, BC, Oct. 05, 2020 /CNW/ – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that Dr. Jennifer Bath, CEO of IPA, was invited Sunday morning, October 4th, as a guest on Fox & Friends with Anchor Jedediah Bila at 7:15a.m. ET.

ImmunoPrecise Antibodies Ltd. Logo (CNW Group/ImmunoPrecise Antibodies Ltd.)

Dr. Bath explained the unique functions of cocktail therapies as they pertain to SARS-CoV-2, including the antibody treatment administered to President Trump.   She also expanded on the importance of the initial design for such strategies and how early steps can be taken to support the safety and efficacy of treatments, but that these tests take time.

IPA launched their Polytope™ Therapy Cocktail, which they believe to be the most promising approach to address a virus like SARS-CoV-2, as it also aims to protect and treat both current and future strains and variants of SARS.

To view Dr. Bath’s interview on Fox & Friends please click here.

About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a global technology platform company with end-to-end solutions empowering companies to discover and develop therapies against any disease. The Company’s experience and cutting-edge technologies enable unparalleled support of its partners in their quest to bring innovative treatments to the clinic. ImmunoPrecise’s full-service capabilities dramatically reduce the time required for, and the inherent risk associated with, conventional multi-vendor product development. For further information, visit www.immunoprecise.com or contact [email protected]

Forward Looking Information
This news release contains statements that, to the extent they are not recitations of historical fact, may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. The Company uses words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “believe”, “intend”, “should” and similar expressions to identify forward-looking statements and include the

Continue Reading

ImmunoPrecise Antibodies CEO Dr. Jennifer Bath Appeared Live, Sunday October 4th, on Fox & Friends | Nachricht

VICTORIA, BC, Oct. 05, 2020 /CNW/ -IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSXV: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development, today announced that Dr. Jennifer Bath, CEO of IPA, was invited Sunday morning, October 4th, as a guest on Fox & Friends with Anchor Jedediah Bila at 7:15a.m. ET.

ImmunoPrecise Antibodies Ltd. Logo (CNW Group/ImmunoPrecise Antibodies Ltd.)

Dr. Bath explained the unique functions of cocktail therapies as they pertain to SARS-CoV-2, including the antibody treatment administered to President Trump.   She also expanded on the importance of the initial design for such strategies and how early steps can be taken to support the safety and efficacy of treatments, but that these tests take time.

IPA launched their Polytope™ Therapy Cocktail, which they believe to be the most promising approach to address a virus like SARS-CoV-2, as it also aims to protect and treat both current and future strains and variants of SARS.

To view Dr. Bath’s interview on Fox & Friends please click here.

About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a global technology platform company with end-to-end solutions empowering companies to discover and develop therapies against any disease. The Company’s experience and cutting-edge technologies enable unparalleled support of its partners in their quest to bring innovative treatments to the clinic. ImmunoPrecise’s full-service capabilities dramatically reduce the time required for, and the inherent risk associated with, conventional multi-vendor product development. For further information, visit www.immunoprecise.com or contact [email protected]

Forward Looking Information
This news release contains statements that, to the extent they are not recitations of historical fact, may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. The Company uses words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “believe”, “intend”, “should” and similar expressions to identify forward-looking statements and include the Company’s beliefs

Continue Reading